ADC THERAPEUTICS SA |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.48 USD | -6.28% |
|
-5.46% | +171.08% |
| Apr. 09 | Transcript : ADC Therapeutics SA - Special Call | |
| Apr. 04 | Sector Update: Health Care Stocks Slump Late Afternoon | MT |
Presentation Operator MessageOperator (Operator)Welcome to the ADC Therapeutics Second Quarter...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkinâs lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.78
USD
Average target price
10.2
USD
Spread / Average Target
+113.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +171.08% | 394M | |
| -2.62% | 104B | |
| +1.61% | 97.42B | |
| +0.82% | 22.2B | |
| -18.07% | 21.23B | |
| -10.74% | 18.33B | |
| -42.33% | 16.35B | |
| -18.10% | 15.06B | |
| +5.40% | 13.98B | |
| +27.60% | 11.66B |
- Stock Market
- Equities
- ADCT Stock
- News ADC Therapeutics SA
- Transcript : ADC Therapeutics SA, Q2 2022 Earnings Call, Aug 09, 2022
